반응식
[CH2:1]([O:8][C:9]1[C:10]2[N:11]([C:15]([C:19]([OH:21])=O)=[C:16]([CH3:18])[N:17]=2)[CH:12]=[CH:13][CH:14]=1)[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.[NH2:22][C@H:23]([CH2:26][CH2:27][CH2:28][CH3:29])[CH2:24][OH:25].CN1CCOCC1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F>ClCCl>[CH2:1]([O:8][C:9]1[C:10]2[N:11]([C:15]([C:19]([NH:22][C@H:23]([CH2:26][CH2:27][CH2:28][CH3:29])[CH2:24][OH:25])=[O:21])=[C:16]([CH3:18])[N:17]=2)[CH:12]=[CH:13][CH:14]=1)[C:2]1[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=1참가 물질
실험 절차
Under argon, 4 g (14.17 mmol) of 8-(benzyloxy)-2-methylimidazo[1,2-a]pyridine-3-carboxylic acid, 1.83 g (15.59 mmol) of (R)-(−)-2-aminohexanol and 7.166 g (70.85 mmol) of 4-methylmorpholine were suspended in 28 ml of dichloromethane. 5 g (15.59 mmol) of TBTU were then added, and the mixture was stirred at room temperature overnight. After 16 h, the mixture was diluted with 200 ml of dichloromethane and washed with 10% strength aqueous citric acid solution, with water and with saturated aqueous sodium chloride solution. The organic phase was concentrated and the residue obtained was purified on a silica gel cartridge (mobile phase dichloromethane:methanol=100:3). Concentration of the product fractions thus gave 3.83 g (71% of theory) of 8-(benzyloxy)-N-[(2R)-1-hydroxyhexan-2-yl]-2-methylimidazo[1,2-a]pyridine-3-carboxamide.
후처리
- waitAfter 16 h
- washwashed with 10% strength aqueous citric acid solution, with water and with saturated aqueous sodium chloride solution
- concentrationThe organic phase was concentrated
- customthe residue obtained
- customwas purified on a silica gel cartridge (mobile phase dichloromethane:methanol=100:3)
출처 및 근거
- ORD 기록
- ord-789816e5fb584b67bd6157953815c035
- 출처 데이터셋
- uspto-grants-2014_07
- 특허 번호
- US08778964B2
연결된 노트
불러오는 중…